Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance

Blood Pressure

Volumn 16, Issue 2, 2007, Pages 95-100

  Nilsson, Peter M ^a   Hedblad, Bo ^a   Donaldson, Jill ^b   Berglund, Göran ^a  

^a LUND UNIVERSITY   (Sweden)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Ambulatory; Blood pressure; Insulin resistance; Rosiglitazone; Trial

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSIGLITAZONE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NIGHT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEDEN; SYSTOLIC BLOOD PRESSURE; TIME; TREATMENT DURATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 34447323014     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050701396652     Document Type: Article

References (34)

1. Ferrannini, E., Buzzigoli, G., Bonadonna, R., Giorico, M. A., Oleggini, M. and Graziadei, L. (1987) Insulin resistance in essential hypertension. N Engl J Med, 317, pp. 350-357.
2. Pollare, T., Lithell, H. and Berne, C. (1990) Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism, 39, pp. 167-174.
3. Nilsson, P., Lind, L., Andersson, P-E., Hänni, A., Berne, C. and Baron, J. (1994) On the use of ambulatory blood pressure recordings and insulin sensitivity in support of the insulin-hypertension hypothesis. J Hypertens, 12, pp. 965-969.
4. Nilsson, P., Lindholm, L. and Scherstén, B. (1992) Lifestyle changes improves insulin resistance in hyperinsulinemic subjects. A one-year intervention study of hypertensives and normotensives in Dalby. J Hypertens, 10, pp. 1071-1078.
5. Dengel, D. R., Hagberg, J. M., Pratley, R. E., Rogus, E. M. and Goldberg, A. P. (1998) Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men. Metabolism, 47, pp. 1075-1082.
6. Lithell, H. O. (1991) Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care, 14, pp. 203-209.
7. Mancia, G., Grassi, G. and Zanchetti, A. (2006) New-onset diabetes and antihypertensive drugs. J Hypertens, 24, pp. 3-10.
8. Qayyum, R. and Adomaityte, J. (2006) A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich), 8, pp. 19-28.
9. Sutton, M. St John, Rendell, M., Dandona, P., Dole, J. F., Murphy, K. and Patwardhan, R. (2002) A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care, 25, pp. 2058-2064.
10. Tan, M. H., Johns, D., Strand, J., Halse, J., Madsbad, S. and Eriksson, J. W. (2004) GLAC Study Group. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med, 21, pp. 859-866.
11. Negro, R., Mangieri, T., Dazzi, D., Pezzarossa, A. and Hassan, H. (2005) Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract, 70, pp. 20-25.
12. Rajagopalan, R., Iyer, S. and Khan, M. (2005) Effect of pioglitazone on metabolic syndrome risk factors: Results of double-blind, multicenter, randomized clinical trials. Curr Med Res Opin, 21, pp. 163-172.
13. Yki-Järvinen, H. (2004) Thiazolidinediones. N Engl J Med, 351, pp. 1106-1118.
14. Sarafidis, P. A., Lasaridis, A. N., Nilsson, P. M., Hitoglou-Makedou, A. D., Pliakos, C. I. and Kiriakos, A. (2004) Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens, 22, pp. 1769-1777.
15. Sarafidis, P. and Nilsson, P. M. (2006) The effects of thiazolidinedione compounds on blood pressure levels - A systematic review. Blood Press, 15, pp. 135-150.
16. Hedblad, B., Nilsson, P. M., Zambanini, A. and Berglund, G. (2007) Rosiglitazone reduces carotid intima-media thickness progression over 1 year in patients with type 2 diabetes but not in non-diabetic people who have insulin resistance alone. J Internal Med, 261, pp. 293-305.
17. Hedblad, B., Nilsson, P., Janzon, L. and Berglund, G. (2000) Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden. Diabetic Med, 17, pp. 299-307.
18. Hedblad, B., Wikstrand, J., Janzon, L., Wedel, H. and Berglund, G. (2001) Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Circulation, 103, pp. 1721-1726.
19. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F. and Turner, R. C. (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, pp. 412-419.
20. Balkau, B., Charles, M. A. and for the European Group for the Study of Insulin Resistance (EGIR) (1999) Comment on the provisional report from the WHO consultation. Diabet Med, 16, pp. 442-443.
21. Turnbull, F. and Blood Pressure Lowering Treatment Trialists' Collaboration (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet, 362, pp. 1527-1535.
22. Mancia, G. and Parati, G. (2003) The role of blood pressure variability in end-organ damage. J Hypertens, 21, pp. S17-S23.
23. Verdecchia, P. (2000) Prognostic value of ambulatory blood pressure. Current evidence and clinical implications. Hypertension, 35, pp. 844-851.
24. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet, 368, pp. 1096-1105.
25. Dormandy, J. A., Charbonnel, B., Eckland, D. J. A., Erdmann, E., Massi-Benedetti, M., Moules, I. K. and on behalf of the PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet, 366, pp. 1279-1289.
26. Bakris, G. L., Ruilope, L. M., McMorn, S. O., Weston, W. M., Heise, M. A. and Freed, M. I. (2006) Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens, 24, pp. 2047-2055.
27. Yosefy, C., Magen, E., Kiselevich, A., Priluk, R., London, D. and Volchek, L. (2004) Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol, 44, pp. 215-222.
28. Pistrosch, F., Passauer, J., Fischer, S., Fuecker, K., Hanefeld, M. and Gross, P. (2004) In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care, 27, pp. 484-490.
29. Vallance, P., Leone, A., Calver, A., Collier, J. and Moncada, S. (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 339, pp. 572-575.
30. Boger, R. H., Bode-Boger, S. M., Szuba, A., Tsao, P. S., Chan, J. R. and Tangphao, O. (1998) Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation, 98, pp. 1842-1847.
31. Stuhlinger, M. C., Abbasi, F., Chu, J. W., Lamendola, C., McLaughlin, T. L. and Cooke, J. P. (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, 287, pp. 1420-1426.
32. Shargorodsky, M., Wainstein, J., Gavish, D., Leibovitz, E., Matas, Z. and Zimlichman, R. (2003) Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in subjects with type 2 diabetes mellitus. Am J Hypertens 2003;16:617-622. Erratum in: Am J Hypertens, 16, p. 84.
33. Bennett, S. M., Agrawal, A., Elasha, H., Heise, M., Jones, N. P. and Walker, M. (2004) Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med, 21, pp. 415-422.
34. Natali, A., Baldeweg, S., Toschi, E., Capaldo, B., Barbaro, D. and Gastaldelli, A. (2004) Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care, 27, pp. 1349-1357.